Oral contraceptives and the risk of hereditary ovarian cancer
Oral contraceptives and the risk of hereditary ovarian cancer
复制标题
DOI：
10.1056/nejm199808133390702
复制
发表时间：
1998-08-13
影响因子：
158.5
通讯作者：
Ponder, BAJ
中科院分区：
文献类型：
--
作者：
Narod, SA;Risch, H;Ponder, BAJ
背景BRCA1或BRCA2基因突变的女性一生中患卵巢癌的风险很高。口服避孕药保护对卵巢癌的一般，但它是不知道他们是否也保护对遗传性卵巢cancer.Methods的形式，我们招募了207名妇女与遗传性卵巢癌和161他们的姐妹篇作为对照的病例对照研究。所有患者均携带BRCA 1（179名女性）或BRCA 2（28名女性）致病突变。对照组的女性无论是否有任何一种突变都被登记入组。口服避孕药的使用寿命的历史，通过采访或书面问卷，并进行了比较，患者和对照组妇女，调整后的出生年份和parad.Results调整后的比值比卵巢癌与任何过去使用口服避孕药为0.5（95%的置信区间，0.3至0.8）。风险随着使用时间的增加而降低（趋势P，
Background Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they also protect against hereditary forms of ovarian cancer.Methods We enrolled 207 women with hereditary ovarian cancer and 161 of their sisters as controls in a case-control study. All the patients carried a pathogenic mutation in either BRCA1 (179 women) or BRCA2 (28 women). The control women were en rolled regardless of whether or not they had either mutation. Lifetime histories of oral-contraceptive use were obtained by interview or by written questionnaire and were compared between patients and control women, after adjustment for year of birth and parity.Results The adjusted odds ratio for ovarian cancer associated with any past use of oral contraceptives was 0.5 (95 percent confidence interval, 0.3 to 0.8). The risk decreased with increasing duration of use (P for trend,